Evidence map›Paper›PMID 32255626›Full record

ArticleBiomacromolecules2020

Control over Imidazoquinoline Immune Stimulation by pH-Degradable Poly(norbornene) Nanogels.

Johannes Kockelmann, Judith Stickdorn, Sabah Kasmi, Jana De Vrieze, Michaela Pieszka, David Yuen W Ng, Sunil A David, Bruno G De Geest, Lutz Nuhn

Open access · hybridAbstract read
In one paragraph

Article in Biomacromolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Johannes KockelmannMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.
Judith StickdornMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.
Sabah KasmiDepartment of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
Jana De VriezeDepartment of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.
Michaela PieszkaMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.
David Yuen W NgMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.ORCID 0000-0002-0302-0678
Sunil A DavidDepartment of Medicinal Chemistry, University of Minnesota, 2231 Sixth Street SE, Minneapolis, Minnesota 55455, United States.
Bruno G De GeestDepartment of Pharmaceutics, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium.ORCID 0000-0001-9826-6170
Lutz NuhnMax Planck Institute for Polymer Research, Ackermannweg 10, 55128 Mainz, Germany.ORCID 0000-0003-0761-1106
Max Planck Institute for Polymer Research · DEGhent University · BEUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The reactivation of the innate immune system by toll-like receptor (TLR) agonists holds promise for anticancer immunotherapy. Severe side effects caused by unspecific and systemic activation of the immune system upon intravenous injection prevent the use of small-molecule TLR agonists for such purposes. However, a covalent attachment of small-molecule imidazoquinoline (IMDQ) TLR7/8 agonists to pH-degradable polymeric nanogels could be shown to drastically reduce the systemic inflammation but retain the activity to tumoral tissues and their draining lymph nodes. Here, we introduce the synthesis of poly(norbornene)-based, acid-degradable nanogels for the covalent ligation of IMDQs. While the intact nanogels trigger sufficient TLR7/8 receptor stimulation, their degraded version of soluble, IMDQ-conjugated poly(norbornene) chains hardly activates TLR7/8. This renders their clinical safety profile, as degradation products are obtained, which would not only circumvent nanoparticle accumulation in the body but also provide nonactive, polymer-bound IMDQ species. Their immunologically silent behavior guarantees both spatial and temporal control over immune activity and, thus, holds promise for improved clinical applications.

Indexed as

ImmunotherapyToll-Like Receptor 7Hydrogen-Ion ConcentrationNanogelsNorbornanesToll-Like Receptor 8NanogelsNorbornanesToll-Like Receptor 7Toll-Like Receptor 8

Identifiers

PMID32255626
PMCPMC7304817
OpenAlexW3014989700

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.